Quick answer: the semaglutide brand name depends on the product: Ozempic is the weekly injection for type 2 diabetes, Wegovy is the injection or daily tablet for weight management and heart risk, and Ozempic tablets (formerly marketed as Rybelsus) are the daily diabetes tablet.[1][2][3][16] Tirzepatide’s brand names are Mounjaro (diabetes) and Zepbound (weight and sleep apnea).[4][5] Retatrutide has no brand name yet, because it is not approved.[15]
Below is every GLP-1 brand sold in the US in 2026, what each is approved for, and which are being discontinued or have generics. For how the drugs work, see our semaglutide profile and how GLP-1 drugs work.
Semaglutide brand names
All semaglutide brands are made by Novo Nordisk.
| Brand | Form | FDA-approved uses |
|---|---|---|
| Ozempic | Weekly injection | Type 2 diabetes; lowering heart attack, stroke and heart death risk in type 2 diabetes with heart disease; lowering kidney decline and heart death risk in type 2 diabetes with chronic kidney disease[1] |
| Wegovy | Weekly injection (including a 7.2 mg pen sold as Wegovy HD) | Weight reduction in adults and children 12 and older; lowering heart risk in adults with heart disease and obesity or overweight; MASH liver disease with moderate to advanced scarring[2] |
| Wegovy tablets | Daily tablet | Weight reduction and heart risk reduction in adults[2] |
| Rybelsus / Ozempic tablets | Daily tablet | Type 2 diabetes; lowering heart risk in high-risk adults with type 2 diabetes[3] |
Why does semaglutide have several brand names?
Each brand is a separate FDA approval with its own uses, doses and label. Ozempic and Wegovy injections contain the same drug, but Wegovy is approved for weight management and goes up to 7.2 mg weekly, while Ozempic tops out at 2 mg.[1][2] Our Wegovy vs Ozempic guide explains the differences, and Rybelsus vs Ozempic compares the pill and the shot.
The newest naming change is on the tablet side. The 2026 Rybelsus label covers both “Rybelsus” and “Ozempic tablets,” which share one label, the same uses and the same warnings.[3] A July 2026 federal court order notes that earlier in 2026 Novo Nordisk stopped marketing the pill under the Rybelsus name and began marketing it as the pill form of Ozempic or Wegovy, depending on the dose.[16] If your prescription says Ozempic tablets, it is oral semaglutide for diabetes, not the injection. See oral vs injectable semaglutide.
Tirzepatide brand names
Tirzepatide is made by Eli Lilly and acts on two hormone receptors, GIP and GLP-1.
| Brand | Form | FDA-approved uses |
|---|---|---|
| Mounjaro (and Mounjaro KwikPen) | Weekly injection | Type 2 diabetes in adults and children 10 and older[4] |
| Zepbound (and Zepbound KwikPen) | Weekly injection | Weight reduction in adults; moderate to severe obstructive sleep apnea in adults with obesity[5] |
Mounjaro and Zepbound contain the same drug. See Zepbound vs Mounjaro and our tirzepatide profile.
Other GLP-1 brand names
| Drug | Brand | Maker | Approved for |
|---|---|---|---|
| Liraglutide | Victoza | Novo Nordisk | Type 2 diabetes (age 10 and up); heart risk in type 2 diabetes with heart disease[6] |
| Liraglutide | Saxenda | Novo Nordisk | Weight reduction (age 12 and up)[7] |
| Dulaglutide | Trulicity | Eli Lilly | Type 2 diabetes (age 10 and up); heart risk reduction[8] |
| Orforglipron | Foundayo | Eli Lilly | Weight reduction in adults (daily pill, approved April 2026)[9] |
| Exenatide | Byetta, Bydureon BCise | AstraZeneca | Discontinued in the US[10][11] |
Two combination products pair a GLP-1 drug with long-acting insulin for type 2 diabetes: Soliqua 100/33 (insulin glargine with lixisenatide, from Sanofi)[13] and Xultophy 100/3.6 (insulin degludec with liraglutide, from Novo Nordisk).[14]
Foundayo is technically different from the others: its label describes orforglipron as a small synthetic molecule (molecular weight about 902), not a chain of amino acids, which is why it can be taken as an ordinary pill. The label also notes that it should not be combined with another GLP-1 drug.[9] See our orforglipron profile.
Brand names by use
- Type 2 diabetes: Ozempic, Rybelsus (Ozempic tablets), Mounjaro, Victoza, Trulicity, Soliqua, Xultophy.
- Weight management: Wegovy (injection and tablets), Zepbound, Saxenda, Foundayo.
- Sleep apnea with obesity: Zepbound.[5]
- MASH liver disease: Wegovy injection, under accelerated approval.[2]
Using a diabetes brand for weight loss is off-label, and insurance coverage usually follows the brand’s approved uses. Our GLP-1 drugs compared guide puts them side by side.
Retatrutide brand name
Retatrutide, Lilly’s experimental triple-hormone drug, has no FDA-approved brand name. FDA states that retatrutide is not a component of any approved drug, has not been found safe and effective for any condition, and cannot be used in compounding.[15] FDA has also warned companies that sold retatrutide labeled “for research purposes” with dosing instructions.[15] A brand name would normally be announced only around approval. For the trial data so far, see our retatrutide profile and retatrutide vs tirzepatide.
Generics and compounded versions
- Liraglutide: FDA has approved generic liraglutide injections from several manufacturers, the first in December 2024.[12] See liraglutide vs semaglutide.
- Semaglutide and tirzepatide: no FDA-approved generics of Ozempic, Wegovy, Rybelsus, Mounjaro or Zepbound were available as of our last review. Read generic semaglutide for the patent timeline.
- Compounded versions: compounded drugs are not FDA-approved and have no brand name. FDA does not review them for safety, effectiveness or quality before they are sold.[15] See compounded semaglutide vs Ozempic.
Same drug, different doses: why the brand on the box matters
Because each brand has its own label, the doses differ even when the drug is the same. Mixing them up can mean taking far more or less than intended.
- Ozempic injection starts at 0.25 mg weekly and can rise in steps to a maximum of 2 mg weekly.[1]
- Wegovy injection also starts at 0.25 mg weekly, but the usual maintenance dose is 2.4 mg, and the Wegovy HD pen allows 7.2 mg.[2]
- Rybelsus tablets start at 3 mg daily and go to 7 mg or 14 mg. Ozempic tablets start at 1.5 mg and go to 4 mg or 9 mg. The label warns that the two tablets are not interchangeable milligram for milligram, even though both are oral semaglutide.[3]
- Wegovy tablets start at 1.5 mg daily, with a maintenance dose of 25 mg daily.[2]
- Mounjaro starts at 2.5 mg weekly, rising in 2.5 mg steps to a maximum of 15 mg in adults.[4]
- Foundayo starts at 0.8 mg daily and can rise to 17.2 mg daily.[9]
Oral semaglutide tablets also have strict instructions: take them on an empty stomach in the morning with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking or taking other pills.[3] Foundayo, by contrast, can be taken with or without food.[9] For conversions between brands, see our GLP-1 dose conversion chart, and never switch without your prescriber.
How to tell which GLP-1 you are taking
- Read the generic name on the label. US prescription labels list the active ingredient, such as semaglutide or tirzepatide, next to or under the brand.
- Check the form and schedule. A weekly pen, a daily pen and a daily tablet are different products, even from the same company.
- Look at the strength. A 7.2 mg semaglutide pen can only be Wegovy HD, and a 25 mg semaglutide tablet is a Wegovy tablet.[2] Lower tablet strengths can overlap between brands, so check the name too.
- Ask the pharmacist. If a refill looks different from the last one, ask before you take it. A changed brand can mean a changed dose.
If your product has no brand name at all, it is likely compounded or sold outside the pharmacy system, and FDA has not reviewed its quality.[15]
Questions to ask your prescriber
- Which brand matches my condition, and will my plan cover it for that use?
- Is a pill or a weekly injection a better fit for me?
- If my brand is unavailable or switched, how do the doses convert?
- Are there approved generics, such as liraglutide, that would cost less?
